Welcome to our dedicated page for Cv Sciences SEC filings (Ticker: CVSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CV Sciences, Inc. filings document the regulatory disclosures of an OTCQB consumer wellness company selling hemp-derived CBD products and other natural wellness formulations. Form 8-K reports cover financial results, Regulation FD disclosures, non-GAAP reconciliations and material agreements tied to secured promissory notes.
The company’s filings also describe capital-structure matters, including note purchase agreements, amendments to secured debt, conversion features, maturity provisions, security interests in company assets and intellectual property, and common stock issuance mechanics. Proxy materials cover annual meeting procedures, director elections, stockholder voting matters and governance items for the Delaware corporation.
CV Sciences, Inc. reported results from its 2026 annual stockholder meeting held virtually on June 2, 2026. There were 193,458,420 shares of common stock outstanding as of the April 6, 2026 record date, and 116,234,784 shares, or about 60.1%, were represented by proxy, establishing a quorum.
Stockholders elected three directors to serve until the next annual meeting: Dr. Jamie Corroon, Joseph Dowling, and Bill McCorkle. A proposal to authorize the board to implement a reverse stock split at a ratio between 1-for-10 and 1-for-800 any time before May 30, 2029 was not approved. Stockholders also ratified the selection of Haskell & White LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
CV Sciences, Inc. reported first quarter 2026 results showing lower sales but improved cost control. Revenue was $3.2 million, down from $3.6 million a year earlier and $3.3 million in the fourth quarter 2025, mainly from lower volumes amid restrictive regulations. Gross margin improved to 48.9% from 46.0% a year ago. Operating expenses (excluding a prior-year payroll tax reversal) fell 13.3% to $1.9 million, and the company posted an operating loss of $0.3 million and a net loss of $0.6 million.
Adjusted EBITDA loss narrowed to about $0.1 million from $0.3 million a year earlier, reflecting tighter expense management. Cash was $0.3 million at March 31, 2026, slightly higher than year-end. Management highlighted a completed debt restructuring to strengthen the balance sheet and noted that products launched since January 2023 contributed 43% of net revenue, supported by 45 new product launches.
CV Sciences, Inc. is asking stockholders to approve routine annual matters and a major capital-structure change at its June 2, 2026 virtual meeting. Stockholders will vote on electing three directors, authorizing a reverse stock split between 1-for-10 and 1-for-800 at the Board’s discretion through May 30, 2029, and ratifying Haskell & White LLP as auditor for 2026. The company had 193,458,420 common shares outstanding as of April 6, 2026, with a majority of voting power required for the reverse split and auditor ratification proposals. The reverse split is intended to increase the share price to support a potential Nasdaq Capital Market listing and expand the investor base, while leaving authorized share counts and par value unchanged.
CV Sciences, Inc. entered into an April 9, 2026 amendment with its institutional investor to modify existing secured convertible notes and a newly issued senior secured convertible note. The amendment lowers the fixed conversion price of the amended notes from $0.06 per share to $0.03 per share.
On April 6, 2026, the company issued a Third Note with a principal amount of $99,614.04, which may be converted into common stock. The Third Note’s conversion price is set at $0.03 per share, based on the lesser of that level and the $0.04 closing price before its original issuance date. The Third Note’s maturity was extended to July 6, 2027.
CV Sciences, Inc. reported 2025 net product sales of $13.8 million, down 12.2% from 2024, while improving gross margin to 49.0% from 45.6%. The company narrowed its net loss to $0.96 million from $2.39 million, helped by cost reductions and lower operating expenses.
The business added plant-based food and softgel manufacturing through the Cultured Foods and Elevated Softgels acquisitions and launched new brands, with products sold in about 2,500 U.S. stores and across Europe. Despite this, cash was $0.28 million and management disclosed substantial doubt about its ability to continue as a going concern, citing intense CBD competition and significant regulatory uncertainty, including a new federal “total THC” cap effective November 2026.
CV Sciences, Inc. reported 2025 revenue of $13.8 million, down from $15.7 million in 2024, but improved profitability metrics. Gross margin rose to 49.0% from 45.6%, and operating loss narrowed to $0.5 million from $2.2 million, with net loss reduced to $0.96 million.
In the fourth quarter, revenue was $3.3 million, slightly above the prior quarter, and the company generated positive adjusted EBITDA of about $0.1 million after a full-year adjusted EBITDA loss of $0.3 million. Management cut operating expenses 17.2% to $7.7 million and attributes the revenue decline mainly to temporary product outages and regulatory headwinds.
Cash ended 2025 at $0.3 million with total assets of $7.0 million and total liabilities of $5.5 million. The company highlights 39 new products since 2023, with 39% of 2025 net revenue from these launches, plus new +PlusCBD and +PlusHLTH offerings and a completed debt restructuring in early 2026 aimed at strengthening its financial position.
CV Sciences, Inc. entered into an agreement with its institutional investor to amend and restate two secured promissory notes into senior secured convertible notes. The Amended Notes now carry a fixed conversion price of $0.06 per share and are initially convertible into 37,600,000 shares of common stock.
The notes’ outstanding principal was increased by 20%, giving an aggregate principal of $2,256,000, and the company eliminated its prior obligation to make monthly redemptions before maturity. A beneficial ownership cap limits the investor to 4.99% of outstanding shares, optionally rising to 9.99% with notice.
A true-up feature aims to ensure the investor’s net sale proceeds equal the principal converted; if the aggregate shortfall across both notes exceeds $94,000, the company will issue a new senior secured convertible note, potentially due April 6, 2027, with no stated cap on shares from that note. The securities were issued without registration under the Securities Act, in reliance on Section 4(a)(2) and/or Regulation D.
CV Sciences, Inc. reported Q3 results marked by softer sales and tight liquidity while taking steps to refinance debt and reduce obligations. Product sales, net were $3.256M versus $3.865M a year ago. Gross profit was $1.579M, and the company posted a net loss of $382K compared to a loss of $456K in Q3 2024.
Cash was $381K as of September 30, 2025, with operating cash use of $53K year‑to‑date. Total assets were $6.995M and stockholders’ equity was $1.539M. The company amended a $1.6M secured note in September 2025 and paid the investor $150K; it also fully repaid a prior Streeterville note, recognizing a $37.5K gain. Subsequent to quarter‑end, it issued a new secured note with original principal of $600K for net proceeds of $300K.
Management disclosed substantial doubt about continuing as a going concern and noted new federal legislation effective November 13, 2026 that will prohibit sales of hemp‑derived products containing more than 0.4 milligrams of total THC per container, which the company is evaluating. Shares outstanding were 184,263,663 as of November 11, 2025.
CV Sciences, Inc. furnished an 8‑K announcing it issued a press release covering financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference into Item 2.02 via Item 7.01.
The release includes non‑GAAP financial measures with GAAP reconciliations and related explanations. The information is furnished, not filed, and includes forward‑looking statements that are subject to risks and uncertainties.